vimarsana.com
Home
Live Updates
Eisai publishes additional detailed analyses from lecanemab
Eisai publishes additional detailed analyses from lecanemab
Eisai publishes additional detailed analyses from lecanemab phase 2b study (2)
STOCKHOLM, March 31, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai...
Related Keywords
Japan ,
Sweden ,
Uppsala ,
Uppsala Lan ,
Stockholm ,
China ,
Swedish ,
Oskar Bosson ,
Washington University School Of Medicine ,
Vp Communications ,
Ministry Of Health ,
Drug Administration ,
National Institutes Of Health ,
Devices Agency ,
European Medicines Agency ,
Uppsala University ,
National Medical Products Administration ,
Alzheimer Clinical Trial Consortium ,
National Institute On ,
Alzheimer Network Trials Unit ,
Alzheimer Research Therapy ,
Nasdaq Stockholm ,
Clinical Dementia Rating Sum Of Boxes ,
Scale Cognitive Subscale ,
Positron Emission Tomography ,
Brand Name ,
Clinical Trials ,
New England Journal ,
Biologics License Application ,
Priority Review ,
Prescription Drug User Fee Act ,
Medical Devices Agency ,
Clinical Trial Consortium ,
National Institute ,
National Institutes ,
Tau Nexgen ,
Dominantly Inherited ,
Washington University School ,
Commercialization Agreement ,
Nasdaq Stockholm Large Cap ,